PD-L1 Biomarkers
News and reporting on PD-L1 biomarkers.
Akoya, Singapore Consortium Collaborate to ID Markers of Response to Checkpoint Inhibitor Therapy
The project will use Akoya's PhenoCode Discovery IO60 Panel to look at matched pairs of immuno-oncology exceptional responders and hyper-progressors.
The company has derived and validated a mutational and gene expression score that predicts immunotherapy benefit across tumor types.
Biomarker Predicts Immunotherapy Benefit in Head and Neck Cancer but Commercial Path Unclear
Premium
Somatic 9p24.1 copy number alterations predicted the degree to which HPV-negative advanced squamous head and neck cancers benefitted from Keytruda and Opdivo.
The firm is aiming to commercialize its OncoPrism assay in 2023 as a laboratory-developed test to identify head and neck cancer patients eligible for checkpoint inhibitors.
Blood-Based PD-L1 Tracking Could Offer Improved Response Prediction for Lung Cancer Immunotherapy
Premium
While the results are from a small study, investigators are working to validate them in larger groups, hoping their method can prove itself for clinical use.